Open AccessStereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer: A Clinical Review as Part of a Health Technology Assessment
Author(s) -
Chantelle C. Lachance,
Khai Tran,
Elizabeth Carson,
Joanne Kim,
David A. Palma,
Shaun K. Loewen,
Tamara Rader,
Danielle MacDougall,
Caitlyn Ford
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.51
Subject(s) - sabr volatility model , medicine , ablative case , radiation therapy , adverse effect , cancer , radiosurgery , medical physics , clinical trial , oncology , volatility (finance) , stochastic volatility , financial economics , economics
Oligometastatic cancer (cancer with a limited number of metastases) represents an intermediate state between cancer confined to a single location in the body and cancer that has metastasized — or spread — widely.One treatment option, for which there is growing interest, is stereotactic ablative radiotherapy, also known as SABR.SABR precisely delivers a high dose of radiation to ablate tumours at specific sites while minimizing the radiation dose to surrounding normal tissues.SABR may be used independently or alongside other treatment options in the management of oligometastatic cancer.This CADTH clinical review evaluated the evidence regarding the clinical effectiveness and safety of SABR with or without standard of care (SOC) for people with oligometastatic cancer and found the following:SABR in addition to SOC may offer a benefit in terms of overall survival (OS) and progression-free survival (PFS).The findings for the effectiveness of SABR alone compared with SOC were mixed and deemed inconclusive.There are insufficient data related to adverse events (AEs) at the present time to draw conclusions regarding the safety of SABR relative to SOC alternatives.Note that the CADTH Clinical Review Report will be updated every 3 months to ensure the findings remain up-to-date as new evidence emerges.